"10.1371_journal.pone.0059397","plos one","2013-03-22T00:00:00Z","Thomas X Lu; Eun-Jin Lim; Svetlana Itskovich; John A Besse; Andrew J Plassard; Melissa K Mingler; Joelle A Rothenberg; Patricia C Fulkerson; Bruce J Aronow; Marc E Rothenberg","Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America; Medical Scientist Training Program, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America; Division of Biomedical Informatics, Department of Pediatrics, Cincinnati Childrens Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America","Interpreted all results: TXL MER. Conceived and designed the experiments: TXL MER. Performed the experiments: TXL EJL SI JAB MKM JAR. Analyzed the data: TXL EJL SI AJP BJA. Contributed reagents/materials/analysis tools: PCF. Wrote the paper: TXL MER.","M. E. Rothenberg has equity interest in reslizumab through Cephalon, is a consultant for Immune Pharmaceuticals, is on the American Partnership for Eosinophilic Disorders Medical Advisory Board, and is on the International Eosinophil Societys Executive Council. The rest of the authors declare that they have no relevant conflicts of interest. Concerning the potential conflict of interest reported, this does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","03","Thomas X Lu","TXL",10,TRUE,2,6,5,2,TRUE,TRUE,FALSE,0,NA,FALSE
